A case of heparin induced thrombocytopenia requiring an open arterial thrombectomy

Authors

  • Jose Lopez General Surgery, Flushing Hospital Medical Center, Flushing, New York, United States
  • Patrick Kiarie St. George’s University, School of Medicine, Grenada, West Indies
  • Bhakti Patel New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York, United States
  • Christina Montesano New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York, United States
  • Christopher Dachowski Ross University School of Medicine, Barbados
  • Martine Louis General Surgery, Flushing Hospital Medical Center, Flushing, New York, United States
  • Manikyam Mutyala General Surgery, Flushing Hospital Medical Center, Flushing, New York, United States

DOI:

https://doi.org/10.18203/2349-2902.isj20263358

Keywords:

Heparin-induced thrombocytopenia, HIT, Acute limb ischemia, Arterial thrombosis, Catheter-directed thrombolysis, Thrombectomy

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication of heparin exposure characterized by thrombocytopenia and a paradoxical prothrombotic state. Although venous thrombosis is more common, arterial thrombosis can result in severe limb-threatening ischemia. A 69-year-old man admitted with new-onset atrial fibrillation and acute systolic heart failure received unfractionated heparin followed by enoxaparin. He subsequently developed a marked decline in platelet count and acute bilateral lower-extremity ischemia. Computed tomography angiography demonstrated extensive thrombi involving the abdominal aorta and bilateral iliac arteries, while venous duplex demonstrated no venous thrombosis. HIT was confirmed by positive anti-PF4 antibodies and serotonin release assay. All heparin products were discontinued and argatroban was initiated. Progressive limb ischemia required catheter-directed EKOS thrombolysis followed by open right common femoral artery thrombectomy, resulting in restoration of lower-extremity perfusion and avoidance of amputation. This presentation was particularly challenging because of concomitant atrial fibrillation and peripheral arterial disease, which provided an alternative explanation for the arterial thrombosis. HIT should be considered in patients with recent heparin exposure who develop thrombocytopenia and unexplained arterial thrombosis, even in the absence of venous thrombosis. Prompt heparin cessation, alternative anticoagulation, and multidisciplinary endovascular and surgical intervention can achieve successful limb salvage.

Metrics

Metrics Loading ...

References

Nicolas D, Nicolas S, Hodgens A, Reed M. Heparin-induced thrombocytopenia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026. Available at: https://www.ncbi.nlm.nih.gov/ books/NBK482330/. Accessed on 16 May 2023.

Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132-5. DOI: https://doi.org/10.1160/TH04-12-0825

Arepally GM, Padmanabhan A. Heparin-induced thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(1):141-52. DOI: https://doi.org/10.1161/ATVBAHA.120.315445

Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S. DOI: https://doi.org/10.1378/chest.11-2303

Ajitha S, Adla Jala SR, Verma R, Chennapragada SS, Pramudita AH, Dandwani M, et al. Trends in heparin-induced thrombocytopenia in the pre-pandemic and peak-pandemic era, and impact of COVID-19 on mortality: an analysis via the National Inpatient Sample. Blood. 2023;142(Suppl 1):5519. DOI: https://doi.org/10.1182/blood-2023-187008

Patriarcheas V, Pikoulas A, Kostis M, Charpidou A, Dimakakos E. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and management. Cureus. 2020;12(3):e7385. DOI: https://doi.org/10.7759/cureus.7385

Ahmed I, Majeed A, Powell R. Heparin-induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575-82. DOI: https://doi.org/10.1136/pgmj.2007.059188

Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-65. DOI: https://doi.org/10.1111/j.1538-7836.2006.01787.x

Crowther M, Pishko A. Management of heparin-induced thrombocytopenia. In: UpToDate. Waltham (MA): UpToDate; 2024. Available at: https://www.uptodate.com/contents/management-of-heparin-induced-thrombocytopenia. Accessed on 08 August 2024.

Marchetti M, Zermatten MG, Bertaggia Calderara D, Aliotta A, Alberio L. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med. 2021;10(4):683. DOI: https://doi.org/10.3390/jcm10040683

Shiuan E, Sharma D, Ely EW, Moodabagil N, Tillman BF. Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection. J Thromb Thrombolysis. 2022;54(2):367-71. DOI: https://doi.org/10.1007/s11239-022-02676-8

Salter BS, Weiner MM, Trinh MA, Heller J, Evans AS, Adams DH, et al. Heparin-induced thrombocytopenia: a comprehensive clinical review. J Am Coll Cardiol. 2016;67(21):2519-32. DOI: https://doi.org/10.1016/j.jacc.2016.02.073

Gurbuz AT, Elliott WG, Zia AA. Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines. Eur J Cardiothorac Surg. 2005;27(1):138-49. DOI: https://doi.org/10.1016/j.ejcts.2004.09.021

Zhang Y, Chen Z, Li J, Wang X, Liu Y. Heparin-induced thrombocytopenia during anticoagulation therapy for COVID-19-related pulmonary embolism: a case report. Medicine (Baltimore). 2024;103(49):e40732. DOI: https://doi.org/10.1097/MD.0000000000040732

Liu X, Huang L, Zhang X, Wu J. Blood hypercoagulability and thrombosis mechanisms in cancer patients: a brief review. Heliyon. 2024;10(19):e38831. DOI: https://doi.org/10.1016/j.heliyon.2024.e38831

Hirashita K, Matsumoto A, Yabuno S, Kanda T, Yunoki M, Yoshino K. A case of posterior circulation ischemic stroke caused by heparin-induced thrombocytopenia after detaining hepatic arterial infusion catheter. J Stroke Cerebrovasc Dis. 2018;27(9):e196-200. DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.04.011

Calligaro KD, Kansagra A, Dougherty MJ, Savarese RP, DeLaurentis DA. Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia. Ann Vasc Surg. 1995;9(4):397-400. DOI: https://doi.org/10.1007/BF02139414

Turba UC, Bozlar U, Simsek S. Catheter-directed thrombolysis of acute lower extremity arterial thrombosis in a patient with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2007;70(7):1046-50. DOI: https://doi.org/10.1002/ccd.21304

Cetingok Sr U, Akkoyun C, Isik Z, Gungor O. Treatment with EkoSonic™ Endovascular System (EKOS®) of massive pulmonary thrombosis following recovery from COVID-19 infection. Cureus. 2022;14(10):e30467. DOI: https://doi.org/10.7759/cureus.30467

Downloads

Published

2026-09-24

How to Cite

Lopez, J., Kiarie, P., Patel, B., Montesano, C., Dachowski, C., Louis, M., & Mutyala, M. (2026). A case of heparin induced thrombocytopenia requiring an open arterial thrombectomy. International Surgery Journal, 13(10), 1991–1996. https://doi.org/10.18203/2349-2902.isj20263358

Issue

Section

Case Reports